MetaCap

Helus Pharma (HELP) vs Neurogene (NGNE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neurogene (NGNE) has outperformed Helus Pharma (HELP) over the past year, gaining 10.4% versus a gain of 9.3%. Over five years, NGNE leads with a -78.3% price change compared with -88.1% for HELP. Helus Pharma is the larger company by market cap ($487.7 million vs $458.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HELP+9.30%NGNE+10.42%
+160%+60%-40%
Nov 21, 20251 yearNov 20, 2026
HELP-90.14%NGNE-79.10%
+9%-45%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HELP versus NGNE key metrics
MetricHELPNGNE
Share price$6.11$22.15
Market cap$487.68M$458.53M
1-day change-9.88%-3.40%
YTD return-25.31%+7.52%
1-year return+9.30%+10.42%
5-year return-88.09%-78.33%
EPS (TTM)$-4.25$-5.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)—$-90.35M
52-week high$15.15$43.66
52-week low$3.76$15.93
Distance from 52-week high-59.67%-49.27%
Analyst consensusnonestrong_buy
Avg. price target upside+564.81%+250.47%
Average volume1.83M307.78K
Shares outstanding79.81M20.70M
Employees100131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Helus Pharma

HELP stock →

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Neurogene

NGNE stock →

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

HELP vs NGNE FAQ

Which is bigger, Helus Pharma or Neurogene?

Helus Pharma (HELP) is larger, with a market capitalization of $487.68M compared with $458.53M for Neurogene (NGNE).

Which stock has performed better over the past year, HELP or NGNE?

NGNE returned +10.42% over the past 12 months, compared with +9.30% for HELP (price return, excluding dividends). Past performance does not predict future results.

Are Helus Pharma and Neurogene in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons